Literature DB >> 9828785

Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma.

S E Coupland1, N Bechrakis, A Schüler, I Anagnostopoulos, M Hummel, N Bornfeld, H Stein.   

Abstract

BACKGROUND/AIMS: A checkpoint mechanism in late G1, whose regulation via loss of retinoblastoma protein (pRB) or p16, or overexpression of cyclin D1 or cyclin dependent kinase 4 (CDK4), has been proposed to constitute a common pathway to malignancy. The aims of this study were (a) to compare markers of cell cycle G1-S phase transition in an intraocular tumour with known pRB deficiency (retinoblastoma) and compare it with one with an apparently functional pRB (uveal melanoma); (b) to determine if one of these markers may have a role in the pathogenesis of uveal melanoma; and (c) to determine if there is a difference in cell cycle marker expression following treatment of uveal melanoma and retinoblastoma.
METHODS: 90 eyes were enucleated from 89 patients for retinoblastoma (n = 24) or for choroidal or ciliary body melanoma (n = 66). Conventional paraffin sections were assessed for cell type and degree of differentiation. Additional slides were investigated applying standard immunohistochemical methods with antibodies specific for cyclin D1 protein, pRB, p53, p21, p16, BCL-2, and MIB-1.
RESULTS: Cyclin D1 protein and pRB were negative in retinoblastoma using the applied antibodies. In contrast, cyclin D1 protein expression was observed in 65% of uveal melanomas; a positive correlation between cyclin D1 cell positivity and tumour cell type, location, growth fraction, as well as with pRB positivity was observed. p53, p21, and p16 could be demonstrated in both tumours. An inverse relation between p53 and p21 expression was demonstrated in most choroidal melanomas and in some retinoblastomas. Apart from a decrease in the growth fractions of the tumours as determined by MIB-1, a significant difference in the expression of G1-S phase transition markers in vital areas of uveal melanoma and retinoblastoma following treatment with radiotherapy and/or chemotherapy was not observed.
CONCLUSION: Retinoblastomas and uveal melanomas, two tumours of differing pRB status, differ also in their immunohistochemical pattern for markers of the G1-S phase transition of the cell cycle. The results of the present study support the concept of (a) an autoregulatory loop between pRB and cyclin D1 in tumours with a functional pRB and the disruption of this loop in the presence of pRB mutation, as well as (b) a checkpoint mechanism in late G1, whose regulation via loss of p16 or pRB, or overexpression of cyclin D1 constitutes a common pathway to malignancy. Further, the results raise the possibility of cyclin D1 overexpression having a role in the pathogenesis of uveal melanoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9828785      PMCID: PMC1722705          DOI: 10.1136/bjo.82.8.961

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  73 in total

1.  Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study.

Authors:  M Sakaguchi; Y Fujii; H Hirabayashi; H E Yoon; Y Komoto; T Oue; T Kusafuka; A Okada; H Matsuda
Journal:  Int J Cancer       Date:  1996-02-08       Impact factor: 7.396

2.  Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.

Authors:  T Tsuzuki; S Tsunoda; T Sakaki; N Konishi; Y Hiasa; M Nakamura
Journal:  Cancer       Date:  1996-07-15       Impact factor: 6.860

3.  Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer.

Authors:  X Gao; Y Q Chen; N Wu; D J Grignon; W Sakr; A T Porter; K V Honn
Journal:  Oncogene       Date:  1995-10-05       Impact factor: 9.867

4.  Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology.

Authors:  I W McLean; W D Foster; L E Zimmerman; J W Gamel
Journal:  Am J Ophthalmol       Date:  1983-10       Impact factor: 5.258

5.  p53 oncoprotein overexpression in choroidal melanoma.

Authors:  K Janssen; J Kuntze; H Busse; K W Schmid
Journal:  Mod Pathol       Date:  1996-03       Impact factor: 7.842

6.  Prognostic significance of Ki67 (MIB1) proliferation index and p53 over-expression in chondrosarcomas.

Authors:  G Nawa; T Ueda; S Mori; H Yoshikawa; H Fukuda; S Ishiguro; H Funai; A Uchida
Journal:  Int J Cancer       Date:  1996-04-22       Impact factor: 7.396

7.  Transformation in recurrent ovarian granulosa cell tumors: Ki67 (MIB-1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior.

Authors:  M J Costa; J Walls; P Ames; L M Roth
Journal:  Hum Pathol       Date:  1996-03       Impact factor: 3.466

8.  Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma.

Authors:  M Ohta; D Berd; M Shimizu; H Nagai; M Mastrangelo; J A Shields; C L Shields; C M Croce; K Huebner
Journal:  Int J Cancer       Date:  1996-03-15       Impact factor: 7.396

9.  Expression of bcl-2 in uveal malignant melanoma.

Authors:  V Jay; Q Yi; W S Hunter; M Zielenska
Journal:  Arch Pathol Lab Med       Date:  1996-05       Impact factor: 5.534

10.  CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine.

Authors:  G A Otterson; S N Khleif; W Chen; A B Coxon; F J Kaye
Journal:  Oncogene       Date:  1995-09-21       Impact factor: 9.867

View more
  20 in total

1.  Telomerase expression in uveal melanoma.

Authors:  B Heine; S E Coupland; S Kneiff; G Demel; N Bornfeld; M Hummel; H Stein
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

Review 2.  Eye cancer: unique insights into oncogenesis: the Cogan Lecture.

Authors:  J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

Review 3.  The genetics of uveal melanoma: an emerging framework for targeted therapy.

Authors:  J William Harbour
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

4.  Deregulation of the Rb and p53 pathways in uveal melanoma.

Authors:  M A Brantley; J W Harbour
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

5.  Effects of proton beam irradiation on uveal melanomas: a comparative study of Ki-67 expression in irradiated versus non-irradiated melanomas.

Authors:  C Chiquet; J D Grange; L Ayzac; P Chauvel; L M Patricot; M Devouassoux-Shisheboran
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

Review 6.  Drosophila as a Potential Model for Ocular Tumors.

Authors:  Daimark Bennett; Ekaterina Lyulcheva; Neville Cobbe
Journal:  Ocul Oncol Pathol       Date:  2015-04-09

Review 7.  Molecular pathology of uveal melanoma.

Authors:  S E Coupland; S L Lake; M Zeschnigk; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

8.  Genetics of uveal melanoma and cutaneous melanoma: two of a kind?

Authors:  Thomas van den Bosch; Emine Kilic; Dion Paridaens; Annelies de Klein
Journal:  Dermatol Res Pract       Date:  2010-06-06

Review 9.  Molecular prognostic testing and individualized patient care in uveal melanoma.

Authors:  J William Harbour
Journal:  Am J Ophthalmol       Date:  2009-10-02       Impact factor: 5.258

10.  Histopathologic and molecular comparative analyses of intravesical Aurora kinase-A inhibitor Alisertib with bacillus Calmette-Guérin on precancerous lesions of bladder in a rat model.

Authors:  Kerem Teke; Hasan Yilmaz; Ali Kemal Uslubas; Gurler Akpinar; Murat Kasap; Oguz Mutlu; Demir Kursat Yildiz; Nil Guzel; Ozdal Dillioglugil
Journal:  Int Urol Nephrol       Date:  2018-06-21       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.